BUZZ-Relay Therapeutics rises on interim data for cancer drug

Reuters2024-12-11

BUZZ-<a href="https://laohu8.com/S/RLAY">Relay Therapeutics</a> rises on interim data for cancer drug

** Shares of Relay Therapeutics RLAY.O rise 7.5% to $4.76 premarket

** Co says its lead drug candidate to treat a type of locally advanced breast cancer helped patients live for about 11.4 months on average without the disease getting worse

** The drug, RLY-2608, is being tested in combination with hormone therapy

** RLAY plans to start a pivotal study testing the combination next year

** The combination was generally well tolerated in the 118 patients treated -RLAY

** Two patients discontinued treatment due to treatment-related side-effects such as nausea and loss of appetite

** Up to last close, stock down ~60% YTD

(Reporting by Mariam Sunny in Bengaluru)

((Mariam.ESunny@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2490858153?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-11 19:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2490858153","market":"us","top_or_hot":-1,"title":"BUZZ-Relay Therapeutics rises on interim data for cancer drug","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/RLAY\">Relay Therapeutics</a> rises on interim data for cancer drug</title></head><body><p>** Shares of Relay <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <span>RLAY.O</span> rise 7.5% to $4.76 premarket   </p><p>** Co says its <span>lead drug candidate</span> to treat a type of locally advanced breast cancer helped patients live for about 11.4 months on average without the disease getting worse    </p><p>** The drug, RLY-2608, is being tested in combination with hormone therapy   </p><p>     ** RLAY plans to start a pivotal study testing the combination next year </p><p>** The combination was generally well tolerated in the 118 patients treated -RLAY</p><p>** Two patients discontinued treatment due to treatment-related side-effects such as nausea and loss of appetite </p><p>** Up to last close, stock down ~60% YTD </p><p> (Reporting by Mariam Sunny in Bengaluru)</p><p> ((Mariam.ESunny@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Relay Therapeutics rises on interim data for cancer drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Relay Therapeutics rises on interim data for cancer drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-11 19:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241211:nL4N3NC0RY:1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BUZZ-Relay Therapeutics rises on interim data for cancer drug** Shares of Relay Therapeutics RLAY.O rise 7.5% to $4.76 premarket   ** Co says its lead drug candidate to treat a type of locally ...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241211:nL4N3NC0RY:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241211:nL4N3NC0RY:1","article_id":"2490858153","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490858153","pubTimestamp":1733917431,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Relay Therapeutics rises on interim data for cancer drug** Shares of Relay Therapeutics RLAY.O rise 7.5% to $4.76 premarket   ** Co says its lead drug candidate to treat a type of locally advanced breast cancer helped patients live for about 11.4 months on average without the disease getting worse    ** The drug, RLY-2608, is being tested in combination with hormone therapy        ** RLAY plans to start a pivotal study testing the combination next year ** The combination was generally well tolerated in the 118 patients treated -RLAY** Two patients discontinued treatment due to treatment-related side-effects such as nausea and loss of appetite ** Up to last close, stock down ~60% YTD   ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","RLAY":"Relay Therapeutics","BK4563":"昨日强势股"},"translate_title":"BUZZ-Relay Therapeutics因癌症药物中期数据而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RLAY":0.9},"content_text":"BUZZ-Relay Therapeutics rises on interim data for cancer drug** Shares of Relay Therapeutics RLAY.O rise 7.5% to $4.76 premarket   ** Co says its lead drug candidate to treat a type of locally advanced breast cancer helped patients live for about 11.4 months on average without the disease getting worse    ** The drug, RLY-2608, is being tested in combination with hormone therapy        ** RLAY plans to start a pivotal study testing the combination next year ** The combination was generally well tolerated in the 118 patients treated -RLAY** Two patients discontinued treatment due to treatment-related side-effects such as nausea and loss of appetite ** Up to last close, stock down ~60% YTD  (Reporting by Mariam Sunny in Bengaluru) ((Mariam.ESunny@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490858153"}